Protective effects of lipocalin-2 (LCN2) in acute liver injury suggest a novel function in liver homeostasis

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1832, Issue 5, 2013, Pages 660-673

  Borkham Kamphorst, Erawan ^a   van de Leur, Eddy ^a   Zimmermann, Henning W ^a   Karlmark, Karlin Raja ^a   Tihaa, Lidia ^a   Haas, Ute ^a   Tacke, Frank ^a   Berger, Thorsten ^b   Mak, Tak W ^b   Weiskirchen, Ralf ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Acute phase response; BDL; CCl4; LCN2; Lipocalin; NGAL

Indexed keywords

AMINOTRANSFERASE; CARBON TETRACHLORIDE; CONCANAVALIN A; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; STAT1 PROTEIN; STAT3 PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; HISTOLOGY; HOMEOSTASIS; HUMAN; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER INJURY; LIVER PROTECTION; MOUSE; NICK END LABELING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ACUTE DISEASE; ACUTE-PHASE PROTEINS; ANIMALS; APOPTOSIS; BILE DUCTS; BLOTTING, WESTERN; CARBON TETRACHLORIDE; CHEMOKINES; CONCANAVALIN A; CYTOKINES; GENE EXPRESSION; HEPATOCYTES; HOMEOSTASIS; HUMANS; IMMUNOHISTOCHEMISTRY; LIGATION; LIPOCALINS; LIPOPOLYSACCHARIDES; LIVER; LIVER DISEASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84874425604     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2013.01.014     Document Type: Article

References (45)

1. Flower D.R. The lipocalin protein family: structure and function. Biochem. J. 1996, 318:1-14.
2. Hraba-Renevey S., Türler H., Kress M., Salomon C., Weil R. SV40-induced expression of mouse gene 24p3 involves a post-transcriptional mechanism. Oncogene 1989, 4:601-608.
3. Kjeldsen L., Johnsen A.H., Sengeløv H., Borregaard N. Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J. Biol. Chem. 1993, 268:10425-10432.
4. Bratt T. Lipocalins and cancer. Biochim. Biophys. Acta 2000, 1482:318-326.
5. Berger T., Cheung C.C., Elia A.J., Mak T.W. Disruption of the Lcn2 gene in mice suppresses primary mammary tumor formation but does not decrease lung metastasis. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:2995-3000.
6. Leng X., Ding T., Lin H., Wang Y., Hu L., Hu J., Feig B., Zhang W., Pusztai L., Symmans W.F., Wu Y., Arlinghaus R.B. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res. 2009, 69:8579-8584.
7. Sunil V.R., Patel K.J., Nilsen-Hamilton M., Heck D.E., Laskin J.D., Laskin D.L. Acute endotoxemia is associated with upregulation of lipocalin 24p3/Lcn2 in lung and liver. Exp. Mol. Pathol. 2007, 83:177-187.
8. Yang J., Mori K., Li J.Y., Barasch J. Iron, lipocalin, and kidney epithelia. Am. J. Physiol. Renal Physiol. 2003, 285:F9-F18.
9. Kjeldsen L., Cowland J.B., Borregaard N. Human neutrophil gelatinase-associated lipocalin and homologous proteins in rat and mouse. Biochim. Biophys. Acta 2000, 1482:272-283.
10. Tong Z., Wu X., Kehrer J.P. Increased expression of the lipocalin 24p3 as an apoptotic mechanism for MK886. Biochem. J. 2003, 372:203-210.
11. Tong Z., Wu X., Ovcharenko D., Zhu J., Chen C.S., Kehrer J.P. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem. J. 2005, 391:441-448.
12. Schmidt-Ott K.M., Mori K., Kalandadze A., Li J.Y., Paragas N., Nicholas T., Devarajan P., Barasch J. Neutrophil gelatinase-associated lipocalin-mediated iron traffic in kidney epithelia. Curr. Opin. Nephrol. Hypertens. 2006, 15:442-449.
13. Mishra J., Mori K., Ma Q., Kelly C., Yang J., Mitsnefes M., Barasch J., Devarajan P. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J. Am. Soc. Nephrol. 2004, 15:3073-3082.
14. Mori K., Lee H.T., Rapoport D., Drexler I.R., Foster K., Yang J., Schmidt-Ott K.M., Chen X., Li J.Y., Weiss S., Mishra J., Cheema F.H., Markowitz G., Suganami T., Sawai K., Mukoyama M., Kunis C., D'Agati V., Devarajan P., Barasch J. Endocytic delivery of lipocalinsiderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J. Clin. Invest. 2005, 115:610-621.
15. Bao G., Clifton M., Hoette T.M., Mori K., Deng S.X., Qiu A., Viltard M., Williams D., Paragas N., Leete T., Kulkarni R., Li X., Lee B., Kalandadze A., Ratner A.J., Pizarro J.C., Schmidt-Ott K.M., Landry D.W., Raymond K.N., Strong R.K., Barasch J. Iron traffics in circulation bound to a siderocalin (Ngal)-catechol complex. Nat. Chem. Biol. 2010, 6:602-609.
16. Schmidt-Ott K.M. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury-where do we stand today?. Nephrol. Dial. Transplant. 2011, 26:762-764.
17. Viau A., El Karoui K., Laouari D., Burtin M., Nguyen C., Mori K., Pillebout E., Berger T., Mak T.W., Knebelmann B., Friedlander G., Barasch J., Terzi F. Lipocalin 2 is essential for chronic kidney disease progression in mice and humans. J. Clin. Invest. 2010, 120:4065-4076.
18. Goetz D.H., Holmes M.A., Borregaard N., Bluhm M.E., Raymond K.N., Strong R.K. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell 2002, 10:1033-1043.
19. Flo T.H., Smith K.D., Sato S., Rodriguez D.J., Holmes M.A., Strong R.K., Akira S., Aderem A. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature 2004, 432:917-921.
20. Berger T., Togawa A., Duncan G.S., Elia A.J., You-Ten A., Wakeham A., Fong H.E., Cheung C.C., Mak T.W. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1834-1839.
21. Ratledge C. Iron metabolism and infection. Food Nutr. Bull. 2007, 28:S515-S523.
22. Borkham-Kamphorst E., Drews F., Weiskirchen R. Induction of lipocalin-2 expression in acute and chronic experimental liver injury moderated by pro-inflammatory cytokines interleukin-1β through nuclear factor-κB activation. Liver Int. 2011, 31:656-665.
23. Roudkenar M.H., Kuwahara Y., Baba T., Roushandeh A.M., Ebishima S., Abe S., Ohkubo Y., Fukumoto M. Oxidative stress induced lipocalin 2 gene expression: addressing its expression under the harmful conditions. J. Radiat. Res. 2007, 48:39-44.
24. Borkham-Kamphorst E., Huss S., Van de Leur E., Haas U., Weiskirchen R. Adenoviral CCN3/NOV gene transfer fails to mitigate liver fibrosis in an experimental bile duct ligation model because of hepatocyte apoptosis. Liver Int. 2012, 32:1342-1353.
25. Zimmermann H.W., Seidler S., Nattermann J., Gassler N., Hellerbrand C., Zernecke A., Tischendorf J.J., Luedde T., Weiskichen R., Trautwein C., Tacke F. Functional contribution of elevated circulating and hepatic non-classical CD14CD16 monocytes to inflammation and human liver fibrosis. PLoS One 2010, 5(6):e11049.
26. Tacke F., Brabant G., Kruck E., Horn R., Schöffski P., Hecker H., Manns M.P., Trautwein C. Ghrelin in chronic liver disease. J. Hepatol. 2003, 38:447-454.
27. + monocyte subset upon liver injury promotes hepatic fibrosis. Hepatology 2009, 50:261-274.
28. Kountouras J., Billing B.H., Scheuer P.J. Prolonged bile duct obstruction: a new experimental model for cirrhosis in the rat. Br. J. Exp. Pathol. 1984, 65:305-311.
29. Arias M., Sauer-Lehnen S., Treptau J., Janoschek N., Theuerkauf I., Buettner R., Gressner A.M., Weiskirchen R. Adenoviral expression of a transforming growth factor-beta1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. BMC Gastroenterol. 2003, 3:29.
30. Borkham-Kamphorst E., Kovalenko E., van Roeyen C.R., Gassler N., Bomble M., Ostendorf T., Floege J., Gressner A.M., Weiskirchen R. Platelet-derived growth factor isoform expression in carbon tetrachloride-induced chronic liver injury. Lab. Invest. 2008, 88:1090-1100.
31. Takeda K., Hayakawa Y., Van Kaer L., Matsuda H., Yagita H., Okumura K. Critical contribution of liver natural killer T cells to a murine model of hepatitis. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5498-5503.
32. Stejskal D., Karpísek M., Humenanska V., Hanulova Z., Stejskal P., Kusnierova P., Petzel M. Lipocalin-2: development, analytical characterization, and clinical testing of a new ELISA. Horm. Metab. Res. 2008, 40:381-385.
33. Haase M., Mertens P.R. Urinary biomarkers-silver bullets to faster drug development and nephron protection. Nephrol. Dial. Transplant. 2010, 25:3167-3169.
34. Wang H., Lafdil F., Kong X., Gao B. Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int. J. Biol. Sci. 2011, 7:536-550.
35. Hong F., Jaruga B., Kim W.H., Radaeva S., El-Assal O.N., Tian Z., Nguyen V.A., Gao B. Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS. J. Clin. Invest. 2002, 110:1503-1513.
36. Sultan S., Pascucci M., Ahmad S., Malik I.A., Bianchi A., Ramadori P., Ahmad G., Ramadori G. LIPOCALIN-2 is a major acute-phase protein in a rat and mouse model of sterile abscess. Shock 2012, 37:191-196.
37. Chakraborty S., Kaur S., Muddana V., Sharma N., Wittel U.A., Papachristou G.I., Whitcomb D., Brand R.E., Batra S.K. Elevated serum neutrophil gelatinase-associated lipocalin is an early predictor of severity and outcome in acute pancreatitis. Am. J. Gastroenterol. 2010, 105:2050-2059.
38. Shapiro N.I., Trzeciak S., Hollander J.E., Birkhahn R., Otero R., Osborn T.M., Moretti E., Nguyen H.B., Gunnerson K.J., Milzman D., Gaieski D.F., Goyal M., Cairns C.B., Ngo L., Rivers E.P. A prospective, multicenter derivation of a biomarker panel to assess risk of organ dysfunction, shock, and death in emergency department patients with suspected sepsis. Crit. Care Med. 2009, 37:96-104.
39. Schroll A., Eller K., Feistritzer C., Nairz M., Sonnweber T., Moser P.A., Rosenkranz A.R., Theurl I., Weiss G. Lipocalin-2 ameliorates granulocyte functionality. Eur. J. Immunol. 2012, 42:3346-3357.
40. Srinivasan G., Aitken J.D., Zhang B., Carvalho F.A., Chassaing B., Shashidharamurthy R., Borregaard N., Jones D.P., Gewirtz A.T., Vijay-Kumar M. Lipocalin 2 deficiency dysregulates iron homeostasis and exacerbates endotoxin-induced sepsis. J. Immunol. 2012, 189:1911-1919.
41. Lippi G., Salvagno G.L., Banfi G. Serum but not urine concentration of neutrophil gelatinase-associated lipocalin is influenced by acute leukocyte variations. Leuk. Lymphoma 2012, 53:1643-1645.
42. Niemann C.U., Walia A., Waldman J., Davio M., Roberts J.P., Hirose R., Feiner J. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transpl. 2009, 15:1852-1860.
43. Gerbes A.L., Benesic A., Vogeser M., Krag A., Bendtsen F., Møller S. Serum neutrophil gelatinase-associated lipocalin - a sensitive novel marker of renal impairment in liver cirrhosis?. Digestion 2011, 84:82-83.
44. Fagundes C., Pépin M.N., Guevara M., Barreto R., Casals G., Solà E., Pereira G., Rodríguez E., Garcia E., Prado V., Poch E., Jiménez W., Fernández J., Arroyo V., Ginès P. Urinary neutrophil gelatinase-associated lipocalin as biomarker in the differential diagnosis of impairment of kidney function in cirrhosis. J. Hepatol. 2012, 57:267-273.
45. Verna E.C., Brown R.S., Farrand E., Pichardo E.M., Forster C.S., Sola-Del Valle D.A., Adkins S.H., Sise M.E., Oliver J.A., Radhakrishnan J., Barasch J.M., Nickolas T.L. Urinary neutrophil gelatinase-associated lipocalin predicts mortality and identifies acute kidney injury in cirrhosis. Dig. Dis. Sci. 2012, 57:2362-2370.